Reasons for discontinuation
| AS (total N=1365) | uSpA (total N=1155) | |||
|---|---|---|---|---|
| All | First 5 years | All | First 5 years | |
| Lack of efficacy | 234 (37.1%) | 213 (36.4%) | 272 (41.7%) | 260 (41.4%) |
| Primary LOE | 114 (18.1%) | 113 (19.3%) | 129 (19.8%) | 129 (20.5%) |
| Secondary LOE | 120 (19.0%) | 100 (17.1%) | 143 (21.9%) | 131 (20.9%) |
| Safety | 183 (29.0%) | 178 (30.4%) | 161 (24.7%) | 157 (25.0%) |
| Remission/inactive disease* | 26 (4.1%) | 25 (4.3%) | 35 (5.4%) | 35 (5.6%) |
| Pregnancy* | 11 (1.7%) | 9 (1.5%) | 16 (2.5%) | 16 (2.5%) |
| Other reasons | 146 (23.1%) | 135 (23.1%) | 111 (17.0%) | 107 (17.0%) |
| Reason missing | 31 (4.9%) | 25 (4.3%) | 57 (8.7%) | 53 (8.4%) |
| Total | 631 | 585 | 652 | 628 |
Percentages are based on the total number of discontinuations in each column.
*The patients discontinuing due to remission/inactive disease or pregnancy were censored in the survival analyses.
AS, ankylosing spondylitis; LOE, lack of efficacy; uSpA, undifferentiated spondyloarthritis.